Remegen Co., Ltd.

This phase 2 trial tested an experimental drug called RC18 in people with relapsing-remitting multiple sclerosis (MS). The goal was to see if RC18 is safe and can reduce the number of MS attacks. Only 8 people took part before the study was stopped early. The drug works by target…

This study tested a drug called RC18 in 178 people with neuromyelitis optica spectrum disorders (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. The goal was to see if RC18 could safely delay or prevent relapses. Participants had to have had recent re…